Resources Repository
-
ArticlePublication 2015Health Gains & Financial Risk Protection by Public Financing in Ethiopia: An ECEA
This article, published in the Lancet Global Health, aims to evaluate the health and financial …
This article, published in the Lancet Global Health, aims to evaluate the health and financial risk protection benefits of selected interventions that could be publicly financed by the government of Ethiopia. The authors used an extended cost-effectiveness analysis (ECEA) to assess the health gains (deaths averted) and financial risk protection afforded (cases of poverty averted) by a bundle of nine interventions that the Government of Ethiopia aims to make universally available. This approach incorporates financial…
Cost-Effectiveness Analysis | Health/Medicine | Sub-Saharan Africa | Health Systems | Priority Setting/Ethics | Mathematical Models | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Policy/Regulation -
ReportPublication 2015Chapter 4: Cervical Cancer
This chapter focuses on the possibility of primary prevention of cervical cancer as a result …
This chapter focuses on the possibility of primary prevention of cervical cancer as a result of the introduction of two commercially available vaccines against human papillomavirus (HPV). Few low- and middle-income countries (LMICs) have initiated or sustained cytology-based cervical cancer prevention programs, and these countries experience very high incidence and mortality rates. Fortunately, alternative strategies to prevent cervical cancer have been investigated and extensively evaluated in these settings. The authors report findings from cost-effectiveness analyses…
Cost-Effectiveness Analysis | Health/Medicine | Global | Health Systems | Mathematical Models | Infectious Diseases | Chronic Disease/Risk | Clinical Care | Science/Technology -
GuidelinesPublication 2013Consolidated Health Economic Evaluation Reporting Standards
These guidelines demonstrate how to present the findings of Health Economic Evaluations. They are aimed …
These guidelines demonstrate how to present the findings of Health Economic Evaluations. They are aimed at researchers and reviewers in no particular region. Previously published checklists or guidance documents related to reporting economic evaluations were identified from a systematic review and subsequent survey of task force members. A two-round, modified Delphi Panel with representatives from academia, clinical practice, industry, and government, as well as the editorial community, was used to identify a minimum set of…
Cost-Effectiveness Analysis | Health/Medicine | Global | Health Systems | Costing Methods | Policy/Regulation -
ReviewPublication 2012Modeling Preventative Strategies Against HPV-Related Disease in Developed Countries
This review article is part of a special supplement on “Comprehensive Control of HPV Infections …
This review article is part of a special supplement on “Comprehensive Control of HPV Infections and Related Diseases.” At the time of its writing, prophylactic vaccination against human papillomavirus (HPV) in pre-adolescent females had been introduced in most developed countries, supported by modeled evaluations that had almost universally found vaccination of pre-adolescent females to be cost-effective. Vaccination of pre-adolescent males had been shown to be cost-effective at a cost per vaccinated individual of ~US$400-500 if…
Cost-Effectiveness Analysis | Health/Medicine | Global | Health Systems | Mathematical Models | Chronic Disease/Risk | Social Determinants -
ReviewPublication 2003Public Health Policy and Cost-Effectiveness Analysis
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to …
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to rigorously evaluate alternatives to reduce mortality from cervical cancer. Scientific advances have provided opportunities over time to revisit strategies for cervical cancer prevention. How to invest health resources wisely, such that public health benefits are maximized-and opportunity costs are minimized-is a critical question in the setting of enhanced cytologic screening methods, human papillomavirus DNA testing, and vaccine development. Developing sound…
Cost-Effectiveness Analysis | Health/Medicine | Global | Health Systems | Mathematical Models | Infectious Diseases | Chronic Disease/Risk | Policy/Regulation -
BookPublication 2003WHO Guide to Cost-Effectiveness Analysis
This 2003 guide provides a method of assessing the cost-effectiveness of health interventions for an …
This 2003 guide provides a method of assessing the cost-effectiveness of health interventions for an international audience. The authors aim to inform the policy maker and to maximize the generalizability of results across settings. Part I begins with a description of cost-effectiveness analysis. It then considers issues relating to study design, estimating costs, assessing health effects, discounting, uncertainty and sensitivity analysis, and reporting results. Part II provides examples to illustrate the principles in Part I. Detailed discussions…
Cost-Effectiveness Analysis | Health/Medicine | Global | Health Systems | Priority Setting/Ethics | Costing Methods | Health Outcomes | Evidence Synthesis | Mathematical Models